NCT05813704已完成不适用
A Prospective, Multicenter Clinical Trial in Evaluating the Safety and Efficacy of the Coronary Crossing System in Patients With Coronary Chronic Total Occlusions
Shanghai MicroPort Rhythm MedTech Co., Ltd.2 个研究点 分布在 1 个国家目标入组 159 人开始时间: 2023年11月7日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 159
- 试验地点
- 2
- 主要终点
- Device success
研究概览
简要总结
This is a prospective and multicenter clinical investigation aiming to evaluate the safety and effectiveness of coronary crossing system for the treatment of patients with coronary chronic total occlusions.
详细描述
This study is divided into two phases. The first phase is the pilot study stage, which is a prospective single-group observational test (FIM phase). The second phase is the pivotal study phase, which is a prospective, multi-center, single-group clinical trial (OPC phase). It is carried out in about 20 hospitals in China.
- Pilot study phase (FIM phase): It is a prospective single-group observational test. It is expected to recruit 10 subjects in a research center in China.
- Pivotal study phase (OPC phase): It is a prospective, multicenter, single-group clinical trial. 146 subjects are expected to be recruited in 20 research centers in China.
- All subjects with coronary chronic total occlusions participating in this clinical study must have only a CTO lesion which occluded in length of more than 5 mm and located in a native coronary artery with a diameter of ≥ 2.50 mm (visual inspection).
- All subjects receive clinical follow-up during hospitalization, 30 days after surgery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical Inclusion Criteria:
- •Aged 18 years and older.
- •Subjects with coronary artery disease who have symptoms of angina pectoris and evidence of ischemia or myocardial viability in the area innervated by the coronary arteries where the CTO is located.
- •Subjects who are able to understand the purpose of the trial, participate voluntarily or by proxy and indicate by signing the informed consent form that they recognize the risks and benefits described in the informed consent document and are willing to undergo clinical follow-up.
- •Angiography Inclusion Criteria:
- •There is only one target CTO that needs to be treated with percutaneous coronary intervention (PCI).
- •Target CTO is located in a native coronary artery with a reference vessel diameter of ≥ 2.5 mm.
- •Angiography showed complete occlusion of the target CTO (visual inspection), antegrade flow of the occluded vessel segment TIMI grade 0 and inferred occlusion time ≥ 3 months; or previous angiographic records confirmed occluded time of the target CTO ≥ 3 months.
- •The target CTO occluded segment length ≥ 5 mm (visual inspection).
- •Angiography of the target CTO showed high density along the vessel, which is considered calcified lesion.
- •The antegrade approach is determined as the primary strategy with guidewire crossing in PCI treatment.
- •The fibrous cap of the target lesion can not be penetrated within 60 seconds using the guidewire with polypolymer coated or tip stiffness > 1.5g (visual inspection) under fluoroscopy and the time is timed when the guidewire reaches the fibrous cap. (To identify chronic total occlusions and exclude acute or subacute occlusions that such guidewire can pass directly).
- •In addition to the target lesion, there must be up to one non-target lesion to be treated and it is located on a different epicardial vessel than the target lesion. Target lesions can be treated after successful treatment of the non-target lesion (residual stenosis < 30% and TIMI 3 flow) without complications.
排除标准
- •General Exclusion Criteria:
- •Acute myocardial infarction within 30 days prior to baseline procedure.
- •Life expectancy < 1 year.
- •Inability to use protocol-required concomitant medications (eg, aspirin, P2Y12 platelet receptor inhibitors, heparin, contrast agents, etc) due to allergy or other contraindications, and no alternative medications.
- •The target CTO has an iatrogenic dissection that occurred within the past 3 months.
- •Left ventricular ejection fraction less than 35%.
- •Severe aortic or mitral valve disease.
- •Planned left ventricular (LV) support device during CTO PCI.
- •Subjects with clear bleeding tendency, contraindications to antiplatelet agents and anticoagulant therapy.
- •Stroke, transient ischemic attack (TIA), or significant gastrointestinal (GI) bleeding within 6 months before the baseline procedure.
- •Planned additional coronary or valvular percutaneous or surgical intervention scheduled within 30 days after baseline procedure.
- •Subjects who require emergent or urgent PCI.
- •Female subjects who are pregnant or breast-feeding.
- •Subjects who are participating in another investigational drug or device clinical trial in which the primary endpoint is still not reached, or intend to participate in another investigational drug or device clinical trial within 12 months after baseline procedure.
- •Other medical illnesses that may cause the subject to be non-compliant with the protocol or confound data interpretation.
- •Serum creatinine > 2.5 mg/dL (or 221 µmol/L), or on dialysis.
- •Hemodynamic instability or severely impaired activity tolerance (KILLIP Class III, IV, or NYHA Class III, IV).
- •Subjects with sustained tachyarrhythmia or cardiogenic shock.
- •Angiography Exclusion Criteria:
- •The target CTO is in an unprotected left main.
- •No angiographically visible collateral flow to the target vessel distal to the occlusion, from ipsilateral or contralateral collaterals.
- •Because of the presence of moderate to severe tortuosity or stenosis in the collateral vessels, retrograde approach is not preferred at the investigator 's discretion.
- •Vessel tortuosity proximal to, or within, body of target occlusion which, in the opinion of the investigator, is not amenable to advancement of a microcatheter or Coronary Crossing System.
研究组 & 干预措施
Coronary Crossing System
Experimental
Subjects in experimental group will be treated with the Coronary Crossing System manufactured by Shanghai Microport Rhythm Co. Ltd.
干预措施: Coronary Crossing System of Shanghai MicroPort Rhythm (Device)
结局指标
主要结局
Device success
时间窗: Baseline procedure
Device success is defined as successful antegrade crossing of the CTO into the true arterial lumen distal to the occlusion following advancement of at least 3 mm of the Coronary Crossing System into any segment as assessed by the core angiographic laboratory. (An antegrade only approach may involve Antegrade Dissection Re-Entry (ADR) with or without the use of specialized devices (e.g. Stingray); absence of successful retrograde crossing of a collateral will still be considered an antegrade only approach.)
次要结局
- Overall device success(Baseline procedure)
- Technical Success(Baseline procedure)
- Procedural Success(Baseline procedure)
- Clinical Success(30 days post-procedure)
- Freedom from device related major adverse event(MAE)(48 hours or until discharge)
- Freedom from major adverse event(MAE)(30 days post-procedure)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Coronary Intravascular Lithotripsy System in Patients With Coronary Artery Calcification (VIGOUR)Coronary Artery CalcificationNCT05818098Shanghai MicroPort Rhythm MedTech Co., Ltd.189
尚未招募
不适用
Trial for MicroPort's DCBCoronary Artery In-stent RestenosisNCT04386213Shanghai MicroPort Medical (Group) Co., Ltd.216
Unknown
不适用
Safety and Efficacy of Rotator Cuff Function Restoration Balloon in Irreparable Rotator Cuff TearRotator Cuff TearsNCT04538001Shanghai MicroPort Medical (Group) Co., Ltd.112
已完成
不适用
Safety and Effectiveness Study of the Solysafe Septal Occluder in Patients With Atrial Septum Defect and Patent Foramen OvaleAtrial Septal DefectPatent Foramen OvaleNCT00207376Carag AG
尚未招募
不适用
Safety and Efficacy of Polyvinyl Alcohol Sodium Acrylate Embolization Microspheres for CRLMColorectal Cancer Liver MetastasisNCT06021015Zhongda Hospital72